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ABSTRACT 28 
Ablation of glucagon receptor signalling represents a potential treatment option for type 2 29 
diabetes (T2DM). Additionally, activation of glucose-dependent insulinotropic polypeptide 30 
(GIP) receptor signalling also holds therapeutic promise for T2DM. Therefore, the present 31 
study examined both independent and combined metabolic actions of 32 
desHis
1
Pro
4
Glu
9
(Lys
12
PAL)-glucagon (glucagon receptor antagonist) and D-Ala
2
GIP (GIP 33 
receptor agonist), in diet induced obese mice. Glucagon receptor binding has been linked to 34 
alpha-helical structure and desHis
1
Pro
4
Glu
9
(Lys
12
PAL)-glucagon displayed enhanced alpha-35 
helical content compared to native glucagon. In clonal pancreatic BRIN-BD11 beta-cells, 36 
desHis
1
Pro
4
Glu
9
(Lys
12
PAL)-glucagon was devoid of any insulinotropic or cAMP generating 37 
actions, and did not impede D-Ala
2
GIP-mediated (p<0.01 to p<0.001) effects on insulin and 38 
cAMP production. Twice daily injection of desHis
1
Pro
4
Glu
9
(Lys
12
PAL)-glucagon or D-39 
Ala
2
GIP alone, and in combination, in high fat fed mice failed to affect body weight or 40 
energy intake. Circulating blood glucose levels were significantly (p<0.05 to p<0.01) 41 
decreased by all treatments regimens, with plasma and pancreatic insulin elevated (p<0.05 to 42 
p<0.001) in all mice receiving D-Ala
2
GIP. Interestingly, plasma glucagon concentrations 43 
were decreased (p<0.05) by sustained glucagon inhibition (day 28), but increased (p<0.05) by 44 
D-Ala
2
GIP therapy, with combined treatment resulting in glucagon concentration similar to 45 
saline controls. All treatments improved (p<0.01) intraperitoneal and oral glucose tolerance, 46 
and peripheral insulin sensitivity. D-Ala
2
GIP treated mice showed increased glucose-induced 47 
insulin secretion in response to intraperitoneal and oral glucose. Metabolic rate and 48 
ambulatory locomotor activity were increased (p<0.05 to p<0.001) in all 49 
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desHis
1
Pro
4
Glu
9
(Lys
12
PAL)-glucagon treated mice. These studies highlight the potential of 50 
glucagon receptor inhibition alone, and in combination with GIP receptor activation, for 51 
T2DM treatment.  52 
 53 
INTRODUCTION 54 
Through advances in our understanding of the pathways involved glucose homeostasis, and 55 
an appreciation that type 2 diabetes (T2DM) is a bi-hormonal disorder, it is clear that 56 
abnormalities of insulin secretion and action in T2DM are present in the setting of glucagon 57 
excess (Unger & Cherrington, 2012). Thus, improved control of glucagon signalling 58 
represents a rational therapeutic target for T2DM. In agreement with this, early proof-of-59 
concept studies using the orally available glucagon receptor antagonist, Bay 27-9955, have 60 
shown initial promise in humans (Petersen & Sullivan, 2001). Additionally, more recent 61 
clinical trials with similar orally available glucagon receptor inhibitors, MK-0893 and LY-62 
2409021, reveal further potential for the treatment of T2DM (Xiong et al. 2012; Kelly et al. 63 
2015). A separate, but somewhat comparable approach, to reduce glucagon receptor 64 
expression through use of antisense oligonucleotides, has also reached Phase 2 clinical trials 65 
(Sehgal et al. 2013.  However, the ultimate approval of these types of low molecular weight 66 
therapies will depend upon specificity and off-target effects, toxicity and potential for 67 
immune responses (Peng et al. 2014; Lefebvre et al. 2015; Kelly et al. 2015).  68 
 Therefore, we have recently characterised the novel peptide-based glucagon receptor 69 
antagonist, desHis
1
Pro
4
Glu
9
(Lys
12
PAL)-glucagon (O’Harte et al. 2014), that should represent 70 
a more specific approach to inhibit glucagon receptor action. Indeed, this peptide analogue 71 
induced significant improvements in metabolic control following a chronic dosing regimen in 72 
diet induced obese (DIO) as well as in ob/ob diabetic mice (O’Harte et al. 2014). Importantly, 73 
we did not observe any evidence of adverse effects, and further studies in normal mice 74 
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indicate that this peptide-based glucagon receptor antagonist represents a safe and effective 75 
treatment option for T2DM (Franklin et al. 2014). Interestingly, Mu and colleagues reported 76 
that co-administration of the glucagon antagonist, Cpd-A, with a dipeptidylpeptidase-4 (DPP-77 
4) inhibitor in diabetic mice resulted in additional improvements in glycaemic control when 78 
compared to either treatment alone (Mu et al. 2011). It follows that combined therapy of a 79 
glucagon receptor antagonist with an incretin based drug could offer an advantageous 80 
approach for the treatment of T2DM.   81 
 The incretin hormones, glucose-dependent insulinotropic polypeptide (GIP) and 82 
glucagon-like peptide-1 (GLP-1), are recognised to account for approximately 50-70% of 83 
insulin secretion following a meal (Nauck et al 1986). However, this incretin contribution to 84 
postprandial insulin release falls to less than 20% in T2DM (Nauck et al. 1986). The 85 
reduction is attributable to decreased GLP-1 release (Vilsboll et al. 2001) and resistance to 86 
the insulinotropic actions of GIP in T2DM (Nauck et al. 1993). Accordingly, enzymatically 87 
stable GLP-1 mimetics that enhance circulating physiological levels of GLP-1 have gained 88 
notable success in the T2DM clinic (Gupta 2013; Chaplin & Joseph 2014), whereas GIP 89 
mimetics are yet to reach the clinic due to insensitivity in T2DM patients (Nauck et al. 1993). 90 
More encouragingly, GIP resistance in T2DM appears to be reversible in both animals and 91 
man through tight glycaemic control or combinational drug therapy (Meneilly et al. 2003; 92 
Piteau et al. 2007; Højberg et al. 2009). In addition to this, there is a suggestion that GIP, 93 
unlike GLP-1, can promote glucagon release (Meier & Nauck 2004, 2015) which would 94 
further detract from its therapeutic efficacy in T2DM. Thus, co-administration of a specific 95 
glucagon receptor antagonist (O’Harte et al. 2014), with a stable long-acting GIP mimetic, 96 
such as D-Ala
2
GIP (Hinke et al. 2002; Gault et al. 2003), should offer a meaningful 97 
therapeutic advantage. 98 
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To evaluate the potential of combined glucagon receptor inhibition and GIP receptor 99 
activation in T2DM, we have investigated the effects of sub-chronic treatment with the peptide-100 
based glucagon receptor antagonist, desHis
1
Pro
4
Glu
9
(Lys
12
PAL)-glucagon, and D-Ala
2
GIP in 101 
DIO mice fed a high fat diet. The results provide experimental evidence that GIP mimetics may 102 
prove to be surprisingly useful for the treatment of T2DM when combined with a glucagon 103 
receptor antagonist. 104 
MATERIALS AND METHODS 105 
Peptide synthesis 106 
Glucagon, D-Ala
2
GIP and desHis
1
Pro
4
Glu
9
(Lys
12
PAL)-glucagon were produced (>95% 107 
purity) by Fmoc solid-phase peptide synthesis and purchased from GL Biochem Ltd. 108 
(Shanghai, China).  All peptides were further characterized in-house using matrix-assisted 109 
laser desorption ionization-time of flight (MALDI-TOF) mass spectrometry, as previously 110 
described (O’Harte et al. 2013).  111 
 112 
Circular dichroism (CD) 113 
CD spectra for glucagon and desHis
1
Pro
4
Glu
9
(Lys
12
PAL)-glucagon were acquired at the far-114 
UV region (190-250 nm) using a JASCO J-810 spectropolarimeter.  Peptide samples were 115 
prepared by dissolving the analogues in water or in 20 mmol/l phosphate buffer at pH 7.0 to a 116 
final concentration of 30 µM and the concentrations of trifluoroethanol (TFE) used was 15%, 117 
30%, 50% and 70% for each peptide. Parameters used for CD experiments were response 118 
time of 2 s, bandwidth of 1 nm, scanning speed of 50 nm/min and a data pitch of 0.2 nm. All 119 
spectra were acquired at 25°C by accumulation of 15 scans in a 1 mm quartz cell, and the 120 
baseline corrected. Calculation of alpha-helical and beta-sheet content was carried out by the 121 
K2D3 program using the DICHROWEB web interface (Louis-Jeune et al. 2012). 122 
 123 
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Acute in vitro insulin release and cAMP measurements 124 
BRIN-BD11 cells were cultured in RPMI-1640 culture medium containing, 10% v/v FBS, 125 
and 11.1 mmol l
-1
 glucose, and were seeded at a density of 1x10
5
 cells/well in 24 well plates 126 
for insulin release studies or 8x10
4
 cells/well in 96 well plates for cAMP studies. Cells were 127 
allowed to attach overnight at 37
o
C in a LEEC incubator (Laboratory Technical Engineering, 128 
Nottingham, UK) in an atmosphere of 5% CO2 and 95% air. Prior to insulin and cAMP 129 
studies, the tissue culture medium was removed and cells were pre-incubated with 1 ml KRB 130 
buffer (pH 7.4) supplemented with bovine serum albumin (0.5% w/v), containing 1.1 mmol/l 131 
glucose at 37
o
C for 40 min.  Test incubations were conducted at 5.6 mmol l
-1
 glucose over a 132 
20 min incubation period, using individual and combined peptide treatments as shown in the 133 
Figures. For insulin release supernatants were removed and frozen at -20
o
C prior to 134 
measurement of insulin by radioimmunoassay (Flatt & Bailey, 1981). For cAMP 135 
measurements cells were lysed and total cAMP content was determined using a commercially 136 
available chemiluminescent cAMP immunoassay kit (R&D Systems Europe Ltd., Abingdon, 137 
UK). 138 
 139 
Animals 140 
NIH Swiss male mice (Harlan Ltd., Oxon, UK) were used at 18 weeks of age. The animals 141 
were housed individually in an air-conditioned room at 22 ± 2
o
C with a 12 h light:12 h dark 142 
cycle (lights off between 20:00 and 08:00 h). All animals had free access to drinking water 143 
and a high fat (45% fat, 35% carbohydrate and 20% protein, Dietex International Ltd. 144 
Witham, Essex, UK) diet for 100 days prior to commencement of studies. Obesity and 145 
glycaemic dysregulation were clearly manifested compared to age matched mice maintained 146 
on normal laboratory chow (10% fat, 30% protein and 60% carbohydrate, Trouw Nutrition, 147 
Cheshire, UK) as verified by body weight and blood glucose analyses.  All experiments were 148 
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conducted in accordance with the UK Animals (Scientific Procedures) Act 1986, under 149 
project licences approved by the local ethical committee. 150 
 151 
Study Design 152 
Mice received twice daily intraperitoneal (i.p.) injections of saline (0.9% NaCl w/v) at 10:00 153 
and 16.30 h, over a 6 day acclimatisation period.  Following this, mice received twice daily 154 
i.p. administration (10:00 and 16.30 h) of saline vehicle (0.9% NaCl w/v) or 155 
desHis
1
Pro
4
Glu
9
(Lys
12
PAL)-glucagon alone, D-Ala
2
GIP alone or a combination of both 156 
peptides (all treatments at 25 nmol kg
-1
 body weight) over a 28 day period. Doses were 157 
chosen based on our previous extensive in vivo assessments with glucagon antagonist and 158 
GIP agonist peptides (Martin et al. 2013; O’Harte et al. 2014).  Food intake was monitored 159 
daily, whereas body weight, circulating blood glucose and plasma insulin concentrations 160 
were assessed at 3-4 day intervals in non-fasted mice at 09.00 h prior to the normal morning 161 
10:00 h peptide administration. At the end of the treatment period, oral and i.p. (18 mmol kg
-1
 162 
bw) glucose tolerance tests were performed in overnight fasted mice. In addition, an insulin 163 
sensitivity (10 U kg
-1 
bw) test was also performed in non-fasted mice. At termination, 164 
pancreatic tissue was excised and insulin content measured following extraction with 5 ml g
-1
 165 
of ice-cold acid ethanol (75% ethanol, 23.5% water, 1.5% concentrated HCl).  166 
 167 
Measurement of metabolic rate and locomotor activity 168 
Metabolic rate and locomotor activity were measured using an Oxymax Complex Laboratory 169 
Animal Monitoring System or CLAMS (Columbus Instruments, OH, USA) on day 28. Mice 170 
were acclimatised to the air tight metabolic chambers for 18 h prior to commencement of 171 
observations. Oxygen consumption and carbon dioxide production were monitored for 30 sec 172 
at 15 min intervals over a period of 24 h and respiratory exchange ratios (RER’s) were 173 
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produced to calculate energy expenditure using the following equation; (3.815 + 1.232 x 174 
RER) x VO2.  Ambulatory locomotor activity was assessed using the optical beams (Opto 175 
M3, Columbus Instruments, OH, USA).  Consecutive photo-beam breaks were scored as an 176 
ambulatory movement. Activity counts in X- and Z- axis were recorded each minute for 24 h. 177 
 178 
Biochemical analyses 179 
Blood samples were collected from the cut tip on the tail vein of conscious mice into chilled 180 
fluoride/heparin glucose micro-centrifuge tubes (Sarstedt, Numbrecht, Germany) at the time 181 
points indicated in the Figures. Blood glucose was measured directly using a hand-held 182 
Ascencia Contour blood glucose meter (Bayer Healthcare, Newbury, Berkshire, UK). For 183 
plasma insulin analysis, blood samples were immediately centrifuged using a Beckman 184 
microcentrifuge (Beckman Instruments, Galway, Ireland) for 1 min at 13,000 x g and stored 185 
at -20°C. Plasma and pancreatic insulin was assayed by a modified dextran-coated charcoal 186 
RIA (Flatt & Bailey, 1981). In addition, a terminal blood sample was also collected for the 187 
measurement of plasma glucagon via a sandwich immunoassay using a commercially 188 
available kit (Meso Scale Discovery, Gaithersburg, Maryland, USA).   189 
 190 
Statistical analyses 191 
Results are expressed as means ± SEM and data compared using ANOVA, followed by a 192 
Student–Newman–Keuls post hoc test. Incremental areas under plasma glucose and insulin 193 
curves (AUC) were calculated using a computer-generated program (Prism 5, CA, USA) 194 
employing the trapezoidal rule with baseline subtraction.  p<0.05 was considered to be 195 
significantly different.   196 
 197 
RESULTS 198 
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Circular dichroism analysis of peptides 199 
In aqueous conditions all peptides had an overall random structure.  Upon addition of TFE, 200 
two negative dichroic bands at 208 nm and 222 nm were observed indicating the formation of 201 
alpha-helical conformations within the peptide analogues. The alpha-helical content of 202 
glucagon was calculated at 26-31% at high TFE concentrations (Fig 1A). As the 203 
concentration of TFE increased, desHis
1
Pro
4
Glu
9
(Lys
12
PAL)-glucagon revealed an overall 204 
trend of increasing alpha-helical concentration with decreased beta-sheet content (Fig 1B). In 205 
comparison to native glucagon (Fig 1A), desHis
1
Pro
4
Glu
9
(Lys
12
PAL)-glucagon had increased 206 
alpha-helical content at 15-70% TFE concentrations (Fig 1B).     207 
 208 
Effects of desHis
1
Pro
4
Glu
9
(Lys
12
PAL)-glucagon and D-Ala
2
GIP on acute insulin secretion 209 
and cAMP production in BRIN-BD11 cells 210 
The acylated glucagon receptor antagonist, desHis
1
Pro
4
Glu
9
(Lys
12
PAL)-glucagon, had no 211 
significant stimulatory effect on either insulin secretion (Fig 2A) or cAMP production (Fig 212 
2B) in BRIN-BD11 cells. However, the stable GIP agonist, D-Ala
2
GIP, induced a significant 213 
(p<0.01 to p<0.001) concentration-dependant (10
-8
 to 10
-6
 M) increase in insulin secretion 214 
when compared with a 5.6 mmol l
-1
 glucose control (Fig 2A). Co-incubation of 215 
desHis
1
Pro
4
Glu
9
(Lys
12
PAL)-glucagon (10
-7 
M) with D-Ala
2
GIP had no effect on D-Ala
2
GIP-216 
mediated insulin release (Fig 2A). Furthermore, desHis
1
Pro
4
Glu
9
(Lys
12
PAL)-glucagon (10
-7 
217 
M) had no inhibitory effect on D-Ala
2
GIP-induced (p<0.01) cAMP production (Fig 2B). 218 
 219 
Effects of 28-days administration of desHis
1
Pro
4
Glu
9
(Lys
12
PAL)-glucagon and D-Ala
2
GIP on 220 
metabolic parameters in high fat diet-induced obese mice 221 
Twice daily treatment with desHis
1
Pro
4
Glu
9
(Lys
12
PAL)-glucagon or D-Ala
2
GIP alone, and in 222 
combination, for 28 days had no significant effect on body weight (Fig 3A) or food intake 223 
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(Fig 3C).  However, total body fat mass was significantly (p<0.01 to p<0.001) reduced in all 224 
treatment groups (Fig 3B), specifically saline control, desHis
1
Pro
4
Glu
9
(Lys
12
PAL)-glucagon 225 
and D-Ala
2
GIP treated high fat mice had body fat masses of 40.3 ± 0.6%, 33.8 ± 0.8% and 226 
37.7 ± 0.5%, respectively, compared to a body fat mass of 37.8 ± 0.5% in lean control mice’.  227 
In addition, D-Ala
2
GIP treated mice and those given the combination of both peptides had 228 
increased (p<0.01) body fat percentage compared to desHis
1
Pro
4
Glu
9
(Lys
12
PAL)-glucagon 229 
treatment alone (Fig 3B). Furthermore, a significant (p<0.05 to p<0.001) decrease in 230 
circulating blood glucose was observed in all three treatment groups from day 10 onwards 231 
when compared to saline controls (Fig 3D). In addition, D-Ala
2
GIP induced a highly 232 
significant (p<0.05 to p<0.001) increase in circulating insulin on day 28 compared to all other 233 
groups (Fig 3E), whereas desHis
1
Pro
4
Glu
9
(Lys
12
PAL)-glucagon monotherapy had no effect 234 
on plasma insulin levels (Fig 3E).  D-Ala
2
GIP mediated elevations in plasma insulin were 235 
partially restrained by combined desHis
1
Pro
4
Glu
9
(Lys
12
PAL)-glucagon therapy, although 236 
values still remained significantly (p<0.05) higher compared to desHis
1
Pro
4
Glu
9
(Lys
12
PAL)-237 
glucagon alone from days 17 through to 28 (Fig 3E). Circulating plasma glucagon 238 
concentrations were significantly (p<0.01) elevated in D-Ala
2
GIP mice compared to saline 239 
and desHis
1
Pro
4
Glu
9
(Lys
12
PAL)-glucagon treated mice at the end of the study, whereas 240 
desHis
1
Pro
4
Glu
9
(Lys
12
PAL)-glucagon treatment alone resulted in a significant (p<0.05) 241 
reduction in glucagon concentrations (Fig 3F). Combined administration of both peptides 242 
resulted in no significant change in plasma glucagon concentrations compared to high fat 243 
control mice (Fig. 3F). Thus, desHis1Pro4Glu9(Lys12PAL)-glucagon prevented the significant 244 
(p<0.05) augmentation of circulating glucagon induced by D-Ala2GIP treatment alone. Interestingly, 245 
the insulin:glucagon molar ratios on day 28 were 23:1, 71:1 and 44:1 in 246 
desHis
1
Pro
4
Glu
9
(Lys
12
PAL)-glucagon, D-Ala
2
GIP and the combined treatment groups, 247 
respectively, compared to 17:1 in saline treated controls.  248 
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 249 
Effects of 28-days administration of desHis
1
Pro
4
Glu
9
(Lys
12
PAL)-glucagon and D-Ala
2
GIP on 250 
glucose tolerance and insulin sensitivity in high fat diet-induced obese mice 251 
All treatment groups had significantly (p<0.05-p<0.01) reduced blood glucose excursions 252 
during an i.p. glucose tolerance test when compared to saline controls (Fig 4A,B). In 253 
addition, D-Ala
2
GIP treatment was associated with a significantly (p<0.01) enhanced overall 254 
insulinotropic response in comparison to control mice (Fig 4C,D).  Similarly, during an oral 255 
glucose challenge, blood glucose levels were significantly (p<0.01) reduced 30 and 60 min 256 
post administration in all treatment groups (Fig 5A).  In harmony with observations following 257 
an i.p. glucose load, D-Ala
2
GIP treatment significantly enhanced the individual (p<0.05 to 258 
p<0.001) and overall (p<0.05) insulin secretory response following oral glucose delivery 259 
when compared to all other groups of mice (Fig 5C,D). Likewise, combined treatment of D-260 
Ala
2
GIP with desHis
1
Pro
4
Glu
9
(Lys
12
PAL)-glucagon also enhanced (p<0.05) the overall 261 
insulin secretory response (Fig 5C,D). As shown in Figure 6, treatment with D-Ala
2
GIP 262 
alone, or in combination with desHis
1
Pro
4
Glu
9
(Lys
12
PAL)-glucagon, significantly (p<0.01) 263 
improved the glucose-lowering action of exogenous insulin at 30 and 60 min post insulin 264 
injection when compared to saline controls (Fig 6A). Treatment with 265 
desHis
1
Pro
4
Glu
9
(Lys
12
PAL)-glucagon alone also resulted in a significant (p<0.01) reduction 266 
in blood glucose levels at 60 min post insulin injection (Fig 6A). Moreover, the overall 267 
glucose-lowering effect of insulin was significantly (p<0.05 to p<0.01) enhanced in all 268 
treatment groups (Fig 6B). Interestingly, pancreatic insulin content was significantly (p<0.05 269 
to p<0.01) higher in mice treated with D-Ala
2
GIP alone, or in combination with 270 
desHis
1
Pro
4
Glu
9
(Lys
12
PAL)-glucagon, when compared to saline controls or 271 
desHis
1
Pro
4
Glu
9
(Lys
12
PAL)-glucagon  treatment alone (Fig 6C).  272 
 273 
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Effects of 28-days administration of desHis
1
Pro
4
Glu
9
(Lys
12
PAL)-glucagon and D-Ala
2
GIP on 274 
metabolic rate and locomotor activity in high fat diet-induced obese mice 275 
Treatment with desHis
1
Pro
4
Glu
9
(Lys
12
PAL)-glucagon alone, and in combination with D-276 
Ala
2
GIP, significantly (p<0.001) increased energy expenditure during the dark phase 277 
compared to saline-treated controls and D-Ala
2
GIP treatment alone (Fig 7A). Respiratory 278 
exchange ratio was not different between groups of mice (Fig 7B). Ambulation, as assessed 279 
by X-beam breaks, was significantly (p<0.05) elevated in mice treated with 280 
desHis
1
Pro
4
Glu
9
(Lys
12
PAL)-glucagon alone, or in combination with D-Ala
2
GIP (Fig 7C). D-281 
Ala
2
GIP treatment did not affect x-beam breaks when compared to control mice (Fig 7C). All 282 
three treatment groups had significantly (p<0.05 to p<0.001) increased numbers of Z-beam 283 
breaks compared to controls, with the combination treatment group also displaying increased 284 
Z-beam breaks when compared to individual treatment regimens (Fig7D). Energy 285 
expenditure, ambulatory activity and Z-beam breaks were not significantly different between 286 
groups during the light phase (data not shown). 287 
 288 
DISCUSSION 289 
Notwithstanding encouraging preclinical data (Bagger et al. 2011; Trujillo & Nuffer 2014), 290 
the progression of monotherapy glucagon antagonist or GIP agonist based therapies to the 291 
clinic is lacking. This is despite knowledge that a potential major beneficial effect of the most 292 
widely used antidiabetic drug, metformin, is mediated through inhibition of glucagon action 293 
(Pernicova & Korkonits 2014). Furthermore, recent studies have shown that targeting 294 
multiple regulatory hormone receptors may be a viable treatment option for T2DM (Patel et 295 
al. 2013; Trevaskis et al. 2013; Skarbaliene et al. 2015).  As such, the dual activation of 296 
incretin-related pathways coupled with glucagon receptor blockade significantly improves 297 
metabolic control in diabetes (Claus et al. 2007; Mu et al. 2011). Given that a documented 298 
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therapeutic drawback of GIP mimetics relates to elevation of glucagon levels (Meier & 299 
Nauck 2004, 2015), combined therapy with a specific glucagon antagonist would seem 300 
logical.  Here we assessed the benefits of combining the glucagon receptor 301 
antagonist desHis
1
Pro
4
Glu
9
(Lys
12
PAL)-glucagon (O’Harte et al. 2014) with the well 302 
characterised DPP-4 resistant GIP analogue, D-Ala
2
GIP (Hinke et al. 2002; Widenmaier et 303 
al. 2010). We aimed to prove the concept that desHis
1
Pro
4
Glu
9
(Lys
12
PAL)-glucagon could 304 
counter GIP-related elevations of blood glucagon levels. 305 
 Structure function studies with native glucagon have shown that the C-terminal 306 
portion of peptide, which exhibits an alpha-helical conformation, is involved in receptor 307 
recognition, with the N-terminal more important for receptor signalling (Sturm et al. 1998). 308 
In the present study, desHis
1
Pro
4
Glu
9
(Lys
12
PAL)-glucagon had an increased α-helical content 309 
when compared with native glucagon, a trait that is strongly associated with increased 310 
receptor binding potency (Krstenansky et al. 1988). As previously shown by the leading 311 
synthetic peptide groups of Hruby and Merrifield, and later independently confirmed in our 312 
laboratory, His
1
, Gly
4
 and Asp
9
 are essential for normal agonist activity of glucagon at the 313 
level of the receptor (Hruby 1982; Unson et al. 1991, 1993; Ahn et al. 2001; O’Harte et al. 314 
2013, McShane et al. 2014; Franklin et al. 2014). In complete harmony with this structural 315 
data, desHis
1
Pro
4
Glu
9
(Lys
12
PAL)-glucagon is known to inhibit glucagon-induced elevations 316 
of cAMP generation and insulin secretion (O’Harte et al. 2013). Both the glucagon and GIP 317 
receptors belong to the same family of G-protein coupled receptors (Brubaker & Drucker, 318 
2002) and share considerable structural homology (Kogire et al. 1992). However, 319 
desHis
1
Pro
4
Glu
9
(Lys
12
PAL)-glucagon did not adversely hinder the insulinotropic and cAMP 320 
potentiating effect of D-Ala
2
GIP (Martin et al. 2013), further confirming specificity. 321 
As would be expected, twice daily treatment with either desHis
1
Pro
4
Glu
9
(Lys
12
PAL)-322 
glucagon or D-Ala
2
GIP in high fat fed mice reproduced many of the beneficial effects 323 
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previously noted with sustained GIP receptor activation (Kerr et al. 2009; Porter et al. 2011) 324 
or glucagon receptor blockade (Lotfy et al. 2014; McShane et al. 2014; O’Harte et al. 2014). 325 
This included significant reductions in circulating blood glucose levels and improvements in 326 
peripheral glucose disposal. Beneficial effects of both treatment regimens were independent 327 
of alterations in body weight or energy intake. Previous studies have indicated that glucagon 328 
can decrease food intake (Habegger et al. 2010; Kosinski et al. 2012), however our studies 329 
with peptide-based glucagon antagonists suggest that contrasting elevations of energy intake 330 
do not occur with glucagon receptor inhibition (Franklin et al. 2014; McShane et al. 2014; 331 
O’Harte et al. 2014). This probably reflects the complex neural pathways and plasticity 332 
involved in the regulation of feeding and energy balance (Dockray & Burdyga 2011). 333 
Combined therapy with desHis
1
Pro
4
Glu
9
(Lys
12
PAL)-glucagon and D-Ala
2
GIP did not result 334 
in discernible benefits on blood glucose or glucose disposal when compared to either 335 
treatment alone. This likely reflects the good efficacy of each treatment alone and the 336 
relatively high doses employed, which could preclude additive action. Indeed, circulating 337 
blood glucose levels were around 5-6 mmol/l in each treatment group by the end of the study. 338 
As has been proposed, circulating glucagon levels were significantly elevated by D-Ala
2
GIP 339 
treatment (Meier & Nauck 2004, 2015), but this detrimental effect was completely annulled 340 
by concurrent administration of desHis
1
Pro
4
Glu
9
(Lys
12
PAL)-glucagon. Moreover, circulating 341 
insulin concentrations were reduced in mice treated with a combination of 342 
desHis
1
Pro
4
Glu
9
(Lys
12
PAL)-glucagon and D-Ala
2
GIP, when compared to D-Ala
2
GIP alone, 343 
implying improved insulin action in these mice, since ambient glucose levels were essentially 344 
similar. Indeed, pancreatic insulin stores and the insulin:glucagon ratio were substantially 345 
augmented by dual therapy on day 28 when compared to desHis
1
Pro
4
Glu
9
(Lys
12
PAL)-346 
glucagon treatment alone, which also points towards decreased insulin demand in the 347 
combined treatment group. Plasma glucagon levels were actually reduced by 348 
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desHis
1
Pro
4
Glu
9
(Lys
12
PAL)-glucagon monotherapy, which is somewhat unexpected given 349 
previous observations (Bagger et al. 2011), and therefore does require further investigation.   350 
Interestingly, total body fat mass was lowered in all treatment groups without change 351 
in overall body weight, suggesting a possible shift towards the use of stored fat as an energy 352 
source. Somewhat surprisingly, although in agreement with increased fat utilisation, energy 353 
expenditure was increased during the dark phase in all mice receiving 354 
desHis
1
Pro
4
Glu
9
(Lys
12
PAL)-glucagon treatment. Thus, glucagon receptor activation is 355 
generally associated with enhanced energy expenditure (Campbell & Drucker 2015) implying 356 
that counter-regulatory mechanisms may be important for the benefits of sustained glucagon 357 
receptor inhibition in the present study. However, respiratory exchange ratio was unaltered 358 
between groups with values of approximately 0.85, indicating a similar combination of fat 359 
and carbohydrates utilisation. Interestingly, mice with genetic knock out of synaptotagmin-7, 360 
a regulator of glucagon and insulin secretion, present with reduced circulating glucagon 361 
levels and increased energy expenditure (Lou et al. 2011), in harmony with the current 362 
findings. Ambulatory locomotion was also elevated only in mice where glucagon receptor 363 
action was inhibited. The overall significance of these centrally mediated effects requires 364 
further detailed elucidation. Moreover, the passage of both desHis
1
Pro
4
Glu
9
(Lys
12
PAL)-365 
glucagon and D-Ala
2
GIP through the blood brain barrier also requires investigation.  366 
Improvements in glucose tolerance and glucose-stimulated insulin release are a 367 
previously reported feature of D-Ala
2
GIP treatment in high fat fed mice (Gault et al. 2011). 368 
Indeed, studies suggest that high fat feeding increases islet GIP receptor expression (Harada 369 
et al. 2008; Moffett et al. 2015). Thus, the GIP analogue may be able to independently 370 
overcome any potential GIP-resistance (Nauck et al. 1993) in this mouse model of T2DM. 371 
Similarly, improvements in response to both oral and intraperitoneal glucose challenge was 372 
observed in desHis
1
Pro
4
Glu
9
(Lys
12
PAL)-glucagon mice, consistent with previous studies 373 
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(O’Harte et al. 2013). This was despite any obvious increase of glucose-stimulated insulin 374 
secretion in desHis
1
Pro
4
Glu
9
(Lys
12
PAL)-glucagon treated mice. In agreement with this, 375 
peripheral insulin sensitivity was dramatically improved by desHis
1
Pro
4
Glu
9
(Lys
12
PAL)-376 
glucagon, however this was also the case for all treatment paradigms. Thus, improved insulin 377 
action might simply be a reflection of decreased glucose toxicity in each treatment group, due 378 
to lower circulating blood glucose concentrations. This might also be a reason for the lack of 379 
benefit of the combined treatment regimen. More interestingly, D-Ala
2
GIP-induced 380 
elevations of insulin secretion appeared to be blunted by co-administration of 381 
desHis
1
Pro
4
Glu
9
(Lys
12
PAL)-glucagon following intraperitoneal glucose, but much less so 382 
following oral glucose administration. This would suggest D-Ala
2
GIP treatment alone, and in 383 
combination with desHis
1
Pro
4
Glu
9
(Lys
12
PAL)-glucagon, enhances the incretin axis in high 384 
fat fed mice (Moffett et al. 2015). Indeed, this could be linked to augmented secretion and/or 385 
action of GLP-1 following an oral glucose challenge in these mice, as suggested previously 386 
(Parker et al. 2002; Gelling et al. 2003). 387 
 In conclusion, the present study indicates that twice daily injection of either D-388 
Ala
2
GIP or desHis
1
Pro
4
Glu
9
(Lys
12
PAL)-glucagon is an effective means of improving 389 
diabetic control in obese-diabetic high fat fed mice. There was some limited evidence for 390 
benefits following combined treatment, but this requires further detailed study to assess the 391 
relative importance. As such, studies utilising various concentration and ratios of individual 392 
peptides could be interesting and might reveal further benefits. Importantly however, 393 
combined therapy of desHis
1
Pro
4
Glu
9
(Lys
12
PAL)-glucagon with D-Ala
2
GIP did completely 394 
annul GIP-induced elevations of circulating glucagon levels and augment pancreatic insulin 395 
stores, confirming proof of concept. Furthermore, it may be interesting to examine the 396 
metabolic benefits of sustained glucagon inhibition in combination with GLP-1 receptor 397 
activation, or in other animal models of diabetes. Taken together the data presented here 398 
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provide evidence for the usefulness of peptide-based GIP receptor agonist and glucagon 399 
receptor antagonist therapies for the treatment of T2DM. 400 
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Figure legends 
Figure 1. Circular dichrosim spectra of (A) glucagon and (B) 
desHis1Pro4Glu9(Lys12PAL)-glucagon. Spectra were observed in the far UV region under 
different concentrations of TFE, as indicated on the figure.  
Figure 2. Insulinotropic and cAMP generating effects of desHis1Pro4Glu9(Lys12PAL)-
glucagon and D-Ala2GIP. (A) BRIN-BD11 cells were exposed to varying concentrations 
(10-12 – 10-6 M) of desHis1Pro4Glu9(Lys12PAL)-glucagon, D-Ala2GIP and D-Ala2GIP in the 
presence of 10-7 M desHis1Pro4Glu9(Lys12PAL)-glucagon for 20 min at 5.6 mmol glucose. 
(A) Extracellular insulin secretion was measured by RIA and total (B) total cAMP generation 
measured by ELISA. Values represent means ± SEM (n=8) where **p<0.01, ***p<0.001 
compared with 5.6 mmol glucose control. ∆∆p<0.01, ∆∆∆p<0.001 compared with 
desHis1Pro4Glu9(Lys12PAL)-glucagon alone. 
Figure 3. Effects of twice daily treatment with desHis1Pro4Glu9(Lys12PAL)-glucagon 
and D-Ala2GIP alone, or in combination on body weight, fat mass, food intake, 
circulating blood glucose, plasma insulin and glucagon concentrations in high fat mice. 
(A, C-E) Parameters were measured 4 days prior to, and 28 days during (indicated by 
horizontal black bar) twice daily treatment with saline vehicle (0.9% w/v NaCl), 
desHis1Pro4Glu9(Lys12PAL)-glucagon, D-Ala2GIP or desHis1Pro4Glu9(Lys12PAL)-glucagon 
in combination with D-Ala2GIP (all at 25 nmol/kg bw) (B,F). Total body fat mass and plasma 
glucagon levels were assessed on day 28.  Values are mean ± SEM for 8 mice. *p<0.05, 
**p<0.01 and ***p<0.001 compared with saline group. ∆p<0.05, ∆∆p<0.01 and ∆∆∆p<0.001 
compared with desHis1Pro4Glu9(Lys12PAL)-glucagon treatment alone. +p<0.05 and ++p<0.01 
compared with combined treatment group.  
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Figure 4. Effects of twice daily treatment with desHis1Pro4Glu9(Lys12PAL)-glucagon 
and D-Ala2GIP alone, or in combination on intraperitoneal glucose tolerance and 
plasma insulin response to glucose in high fat mice. Tests were conducted after 28 days 
twice daily treatment with saline vehicle (0.9% w/v NaCl), desHis1Pro4Glu9(Lys12PAL)-
glucagon, D-Ala2GIP or desHis1Pro4Glu9(Lys12PAL)-glucagon in combination with D-
Ala2GIP (all at 25 nmol/kg bw). (A,C) Glucose (18 mmol/kg bw) was administered by i.p. 
injection at t=0 in 18 h fasted mice.  (B,D) Blood glucose and plasma insulin AUC values for 
0-60 min post injection are also shown. Values are mean ± SEM for 8 mice. *p<0.05, 
**p<0.01 and ***p<0.001 compared with saline group. ∆p<0.05 compared with 
desHis1Pro4Glu9(Lys12PAL)-glucagon treatment alone. 
Figure 5. Effects of twice daily treatment with desHis1Pro4Glu9(Lys12PAL)-glucagon 
and D-Ala2GIP alone, or in combination on oral glucose tolerance and plasma insulin 
response to glucose in high fat mice. Tests were conducted after 28 days twice daily 
treatment with saline vehicle (0.9% w/v NaCl), desHis1Pro4Glu9(Lys12PAL)-glucagon, D-
Ala2GIP or desHis1Pro4Glu9(Lys12PAL)-glucagon in combination with D-Ala2GIP (all at 25 
nmol/kg bw). (A,C) Glucose (18 mmol/kg bw) was administered by oral gavage at t=0 in 18 
h fasted mice. (B,D) Blood glucose and plasma insulin AUC values for 0-60 min post 
injection are also shown. Values are mean ± SEM for 8 mice. *p<0.05, **p<0.01 and 
***p<0.001 compared with the saline-treated control group. ∆p<0.05 and ∆∆p<0.01 compared 
with desHis1Pro4Glu9(Lys12PAL)-glucagon treatment alone. +p<0.05 compared with 
combined treatment group.  
 
 
Page 27 of 43
3 
 
Figure 6. Effects of twice daily treatment with desHis1Pro4Glu9(Lys12PAL)-glucagon 
and D-Ala2GIP alone, or in combination on peripheral insulin sensitivity and pancreatic 
insulin content in high fat mice. Tests were conducted after 28 days twice daily treatment 
with saline vehicle (0.9% w/v NaCl), desHis1Pro4Glu9(Lys12PAL)-glucagon, D-Ala2GIP or 
desHis1Pro4Glu9(Lys12PAL)-glucagon in combination with D-Ala2GIP (all at 25 nmol/kg 
bw). (A) Insulin (10 U/kg bw) was administered by i.p. injection at t=0 in non-fasted mice. 
(B) Blood glucose AAC values for 0-60 min post injection are also shown, where baseline is 
100%. (C) Pancreatic insulin content was assessed on day 28 following acid-ethanol 
extraction and measurement of insulin concentrations by RIA. Values are mean ± SEM for 8 
mice. *p<0.05 and **p<0.01 compared with saline-treated control group. ∆p<0.05 compared 
with desHis1Pro4Glu9(Lys12PAL)-glucagon treatment alone. +p<0.05 compared with 
combined treatment group.  
Figure 7. Effects of twice daily treatment with desHis1Pro4Glu9(Lys12PAL)-glucagon 
and D-Ala2GIP alone, or in combination on metabolic rate and locomotor activity in 
high fat mice. Parameters were measured after 28 days twice daily treatment with saline 
vehicle (0.9% w/v NaCl), desHis1Pro4Glu9(Lys12PAL)-glucagon, D-Ala2GIP or 
desHis1Pro4Glu9(Lys12PAL)-glucagon in combination with D-Ala2GIP (all at 25 nmol/kg 
bw). (A) Energy expenditure, (B) respiratory exchange ratio, (C) ambulatory X counts and 
(D) total Z counts were assessed by CLAMS. Values are mean ± SEM for 6 mice. *p<0.05 
and ***p<0.001 compared with saline group. ∆p<0.05 and ∆∆∆p<0.001 compared with 
desHis1Pro4Glu9(Lys12PAL)-glucagon treatment alone. +p<0.05, ++p<0.01 and +++p<0.001 
compared with combined treatment group.  
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